United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek Sells 4,000 Shares

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 4,000 shares of the business’s stock in a transaction on Monday, April 7th. The shares were sold at an average price of $284.55, for a total value of $1,138,200.00. Following the transaction, the director now owns 1,750 shares of the company’s stock, valued at approximately $497,962.50. The trade was a 69.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Price Performance

NASDAQ UTHR opened at $279.69 on Wednesday. The company has a market cap of $12.56 billion, a price-to-earnings ratio of 12.28, a PEG ratio of 0.97 and a beta of 0.63. The stock’s fifty day moving average price is $328.54 and its 200 day moving average price is $353.09. United Therapeutics Co. has a 1 year low of $230.39 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the company earned $4.36 earnings per share. Research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Wealthfront Advisers LLC lifted its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares during the period. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $151,764,000. FMR LLC boosted its stake in shares of United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares during the last quarter. GAMMA Investing LLC grew its holdings in United Therapeutics by 29,415.2% during the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock worth $68,422,000 after acquiring an additional 221,202 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after acquiring an additional 189,967 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UTHR. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.